A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

Project: Research project

Description

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn's Disease
StatusFinished
Effective start/end date2/21/173/22/18

Funding

  • Celgene Corporation

Fingerprint

Crohn Disease
Multicenter Studies
Placebos
Safety
Therapeutics
GED0301